CLINICAL_TRIALS
ClinicalTrials.gov record update
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02447679
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:36:18.192337+00:00
- Published At
- 2017-02-07T00:00:00+00:00
- Record Updated At
- 2017-02-07
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Adult Hepatocellular Carcinoma", "Recurrent Hepatocellular Carcinoma", "Adverse Reaction to Drug", "Vascular Endothelial Growth Factor Overexpression"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-02-07"- protocolSection.identificationModule.nctId
"NCT02447679"- protocolSection.identificationModule.officialTitle
"Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.